Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089861 | 1.00 | HDAC4 (0.51) | HDAC4GRIN1GRIN2ASLC6A4GRIN2D | |
| SCHEMBL27035066 | 0.94 | HDAC4 (0.49) | HDAC4GRIN1GRIN2ASLC6A4GRIN2D | |
| SCHEMBL9442653 | 0.81 | HDAC4 (0.56) | HDAC4GRIN1GRIN2ASLC6A4GRIN2D | |
| SCHEMBL6058582 | 0.80 | MEN1 (0.41) | HDAC4LMNAHSD17B10 | |
| SCHEMBL29484741 | 0.80 | MEN1 (0.41) | HDAC4LMNAHSD17B10 | |
| SCHEMBL17733195 | 0.80 | MEN1 (0.41) | HDAC4LMNAHSD17B10 | |
| SCHEMBL23210134 | 0.80 | OPRM1 (0.44) | HDAC4OPRK1OPRM1DRD2DRD4 | |
| SCHEMBL652087 | 0.80 | SIGMAR1 (0.57) | HDAC4GRIN1GRIN2ASLC6A4OPRK1 | |
| SCHEMBL29691231 | 0.80 | OPRM1 (0.44) | HDAC4OPRK1OPRM1DRD2DRD4 | |
| SCHEMBL21077808 | 0.77 | DRD2 (0.49) | HDAC4OPRK1OPRM1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA PHARM INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12466783-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | ACADIA PHARMACEUTICALS INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4393487-A2 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA Pharmaceuticals Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3215147-B1 | NEURO-ATTENUATING NORKETAMINE COMPOUNDS AND METHODS | ACADIA PHARM INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230192593-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA PHARMACEUTICALS INC. | 2023-06-22 | — | — | US | disclosed |
| US-11613515-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | AMORSA THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-11603348-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | AMORSA THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220402863-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | AMORSA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220106258-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | AMORSA THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3463323-B1 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | SMALL PHARMA LTD (GB) | 2021-10-20 | — | — | EP | disclosed |
| US-10981859-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | AMORSA THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190263749-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA PHARMACEUTICALS INC. | 2019-08-29 | — | — | US | disclosed |
| US-10252982-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | AMORSA THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170355663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | ACADIA PHARMACEUTICALS INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017208031-A1 | SOLID ORAL DOSAGE FORMS OF 2R,6R-HYDROXYNORKETAMINE OR DERIVATIVES THEREOF | SMALL PHARMA LTD (GB) | 2017-12-07 | — | — | WO | disclosed |
| EP-3215147-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | Amorsa Therapeutics, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073653-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | AMORSA THERAPEUTICS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-5583000-A | DETECTING PRESENCE OF RETROVIRAL PROTEASES IN SAMPLE BY COMBINING WITH SPECIFIED COMPOUND AND DETECTING PRESENCE OF COMPLEXES FORMED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192593-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | KCNK4, GRIK4, KCNK5 | HDAC4 394/4885GRIN1 93/4885GRIN2A 78/4885 |
| US-20220402863-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | KCNK4, KCNQ4, GRIK4 | HDAC4 391/4885GRIN1 75/4885GRIN2A 55/4885 |
| US-11613515-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | KCNK4, GRIK4, KCNK5 | HDAC4 394/4885GRIN1 93/4885GRIN2A 78/4885 |
| US-10981859-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | KCNK4, KCNQ4, GRIK4 | HDAC4 391/4885GRIN1 75/4885GRIN2A 55/4885 |
| US-20220106258-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | KCNK4, GRIK4, KCNK5 | HDAC4 394/4885GRIN1 93/4885GRIN2A 78/4885 |
| US-20260109663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | SLC6A4, KCNK4, KCNJ11 | HDAC4 248/4885GRIN1 82/4885GRIN2A 116/4885 |
| US-11603348-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | KCNK4, GRIK4, KCNK5 | HDAC4 394/4885GRIN1 93/4885GRIN2A 78/4885 |
| US-20170355663-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | KCNK4, GRIK4, KCNQ4 | HDAC4 340/4885GRIN1 70/4885GRIN2A 51/4885 |
| US-10252982-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | KCNK4, GRIK4, KCNQ4 | HDAC4 340/4885GRIN1 70/4885GRIN2A 51/4885 |
| US-12466783-B2 | Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods | KCNK4, GRIK4, KCNK5 | HDAC4 394/4885GRIN1 93/4885GRIN2A 78/4885 |
| US-20190263749-A1 | NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS | KCNK4, KCNQ4, GRIK4 | HDAC4 384/4885GRIN1 78/4885GRIN2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.